4th Annual Wet AMD and Diabetic Eye Disease Drug Development Summit

The 4th Annual Wet AMD and Diabetic Eye Disease Drug Development Summit covers topics such as:

• Improving clinical trial design for retinal vascular diseases to better showcase drug efficacy & fast-track more drugs into the market
• Current anti-VEGF therapies in the spotlight to illuminate the path to more efficacious retinal neovascularization therapies through the pipeline
• Novel preclinical models & approaches to tackle translational challenges when developing treatment for retinal neovascularization
• New treatment modalities to reduce reliance on frequent anti-VEGF injections & cater for the untreated patient population
• Treating retinal vascular inflammation to slow down & eventually halt disease progression to retinal neovascularization
• Developing durable drug formulation & half-life extension to achieve prolonged drug exposure within the retinal vasculature
• Current regulatory guidelines & requirements to fast-track the progression of novel therapeutics
• Novel targets beyond the VEGF pathway to treat neovascularization
• Retinal imaging & clinical biomarkers to better assess disease progression into neovascularization in the eye